Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.2 - $2.73 $281,007 - $639,292
234,173 New
234,173 $316,000
Q3 2022

Nov 14, 2022

SELL
$1.9 - $8.63 $3,230 - $14,671
-1,700 Reduced 12.89%
11,489 $28,000
Q2 2022

Aug 15, 2022

SELL
$2.13 - $9.01 $22,356 - $94,568
-10,496 Reduced 44.31%
13,189 $32,000
Q1 2022

May 13, 2022

BUY
$6.28 - $15.59 $148,741 - $369,249
23,685 New
23,685 $189,000
Q2 2021

Aug 16, 2021

SELL
$26.09 - $40.4 $1.53 Million - $2.37 Million
-58,748 Closed
0 $0
Q1 2021

May 18, 2021

BUY
$33.06 - $56.93 $1.59 Million - $2.75 Million
48,240 Added 459.08%
58,748 $2.24 Million
Q4 2020

Feb 16, 2021

BUY
$39.09 - $57.4 $89,164 - $130,929
2,281 Added 27.73%
10,508 $439,000
Q3 2020

Nov 16, 2020

BUY
$28.43 - $44.67 $233,893 - $367,500
8,227 New
8,227 $357,000

Others Institutions Holding NVTA

About Invitae Corp


  • Ticker NVTA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 235,266,000
  • Description
  • Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...
More about NVTA
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.